Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating in a research note issued to investors on Monday, April 28th,Zacks.com reports.
SNY has been the topic of a number of other research reports. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $63.33.
Read Our Latest Stock Analysis on SNY
Sanofi Price Performance
Shares of SNY traded down $0.52 during mid-day trading on Monday, hitting $54.07. 1,303,562 shares of the company were exchanged, compared to its average volume of 2,783,687. The stock has a market cap of $136.59 billion, a price-to-earnings ratio of 21.71, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a 50 day moving average of $54.53 and a 200-day moving average of $52.03. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business's revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.78 earnings per share. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Sanofi
A number of hedge funds have recently added to or reduced their stakes in the business. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter valued at $25,000. McClarren Financial Advisors Inc. grew its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in Sanofi in the fourth quarter valued at approximately $31,000. Bessemer Group Inc. lifted its stake in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the last quarter. Finally, Golden State Wealth Management LLC grew its holdings in Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.
About Sanofi
(
Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
